When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term ...

Another factor that has likely contributed to the steep decline in NVO’s stock price is the removal of Lilly’s tirzepatide injection products ... the failure of CagriSema to achieve the ...

Should CagriSema face approval delays or not receive approval, its potential sales are expected to benefit existing treatments like Wegovy and Zepbound. In terms of production and injection leaders, ...

Despite CagriSema’s superior performance compared to the individual ... They also pointed to Lilly's focus on innovations such as a one-chamber auto-injector, which could further distinguish it from ...

CagriSema, administered as a subcutaneous weekly injection, demonstrated a 22.7% body weight reduction based on the trial product estimand, or 20.4% according to the treatment policy estimand. The ...

CagriSema is a fixed-dose combination of a ... Recently, the FDA removed Lilly’s tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently ...